drugset / Trial / NCT00193570
Topotecan in Combination With Docetaxel in Refractory and/or Advanced Solid Tumors
Phase 1
Completed
20 enrolled
SCRI Development Innovations, LLC
Genentech, Inc. · collabGlaxoSmithKline · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase I study will characterize the safety, tolerability, and maximum tolerated dose and dose-limiting toxicity of weekly bolus Topotecan when administered in combination with to different dosing regimens of docetaxel. We will also evaluate any anti-tumor activity of the combination regimen.
Timeline
- Start
- 2002-02
- Primary completion
- 2004-08
- Completion
- 2009-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | — | — |
| Subject | Topotecan | Small molecule | — | — |